CN1984903A - 1－(吲哚－6－羰基－d－苯基甘氨酰基)－4－(1－甲基哌啶－4－基)哌嗪d－酒石酸盐 - Google Patents

1－(吲哚－6－羰基－d－苯基甘氨酰基)－4－(1－甲基哌啶－4－基)哌嗪d－酒石酸盐 Download PDF

Info

Publication number
CN1984903A
CN1984903A CNA2005800214090A CN200580021409A CN1984903A CN 1984903 A CN1984903 A CN 1984903A CN A2005800214090 A CNA2005800214090 A CN A2005800214090A CN 200580021409 A CN200580021409 A CN 200580021409A CN 1984903 A CN1984903 A CN 1984903A
Authority
CN
China
Prior art keywords
tartrate
indole
piperazine
carbonyl
methylpiperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800214090A
Other languages
English (en)
Chinese (zh)
Inventor
J·K·布什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1984903A publication Critical patent/CN1984903A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2005800214090A 2004-06-30 2005-06-13 1－(吲哚－6－羰基－d－苯基甘氨酰基)－4－(1－甲基哌啶－4－基)哌嗪d－酒石酸盐 Pending CN1984903A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58359904P 2004-06-30 2004-06-30
US60/583,599 2004-06-30

Publications (1)

Publication Number Publication Date
CN1984903A true CN1984903A (zh) 2007-06-20

Family

ID=35276192

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800214090A Pending CN1984903A (zh) 2004-06-30 2005-06-13 1－(吲哚－6－羰基－d－苯基甘氨酰基)－4－(1－甲基哌啶－4－基)哌嗪d－酒石酸盐

Country Status (19)

Country Link
US (1) US20070249623A1 (cg-RX-API-DMAC7.html)
EP (1) EP1763521A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008505075A (cg-RX-API-DMAC7.html)
CN (1) CN1984903A (cg-RX-API-DMAC7.html)
AR (1) AR049659A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005267579A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0512245A (cg-RX-API-DMAC7.html)
CA (1) CA2570634A1 (cg-RX-API-DMAC7.html)
EA (1) EA010307B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP067105A (cg-RX-API-DMAC7.html)
IL (1) IL179903A0 (cg-RX-API-DMAC7.html)
MA (1) MA28842B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06015112A (cg-RX-API-DMAC7.html)
NO (1) NO20070486L (cg-RX-API-DMAC7.html)
PE (1) PE20060480A1 (cg-RX-API-DMAC7.html)
SV (1) SV2006002156A (cg-RX-API-DMAC7.html)
TW (1) TW200603806A (cg-RX-API-DMAC7.html)
WO (1) WO2006011955A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200610091B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107365304A (zh) * 2017-08-01 2017-11-21 齐宜涛 一种治疗心血管疾病的化合物及制备方法和应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
JP2002539194A (ja) * 1999-03-15 2002-11-19 ノボ ノルディスク アクティーゼルスカブ 新規の（２ｒ，３ｒ，４ｒ）−３，４−ジヒドロキシ−２−ヒドロキシメチルピロリジンの塩
WO2000076971A2 (en) * 1999-06-14 2000-12-21 Eli Lilly And Company Serine protease inhibitors
US6448293B1 (en) * 2000-03-31 2002-09-10 Pfizer Inc. Diphenyl ether compounds useful in therapy
GB0030304D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GEP20053712B (en) * 2001-05-14 2005-12-26 Pfizer Prod Inc Tartrate Salts of 5,8,14-Triazatetracyclo {10.3.1.0²,11.04,9}-Hexadeca-2(11),3,5,7,9-Pentaene and Pharmaceutical Compositions Thereof
TWI257389B (en) * 2001-06-12 2006-07-01 Lilly Co Eli Pharmaceutical compound

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107365304A (zh) * 2017-08-01 2017-11-21 齐宜涛 一种治疗心血管疾病的化合物及制备方法和应用

Also Published As

Publication number Publication date
ECSP067105A (es) 2007-01-26
MA28842B1 (fr) 2007-09-03
CA2570634A1 (en) 2006-02-02
AR049659A1 (es) 2006-08-23
SV2006002156A (es) 2006-02-15
EA200700186A1 (ru) 2007-06-29
MXPA06015112A (es) 2007-02-08
AU2005267579A1 (en) 2006-02-02
BRPI0512245A (pt) 2008-02-19
JP2008505075A (ja) 2008-02-21
IL179903A0 (en) 2007-05-15
TW200603806A (en) 2006-02-01
EA010307B1 (ru) 2008-08-29
NO20070486L (no) 2007-01-25
ZA200610091B (en) 2008-02-27
PE20060480A1 (es) 2006-07-13
US20070249623A1 (en) 2007-10-25
WO2006011955A1 (en) 2006-02-02
EP1763521A1 (en) 2007-03-21

Similar Documents

Publication Publication Date Title
KR101358574B1 (ko) Ｘａ 인자 억제제, ｎ­（5­클로로­2­피리디닐）­2­［［4­［（디메틸아미노）이미노메틸］벤조일］아미노］­5­메톡시­벤자마이드의 약제학적 염 및 다형체
AU2013329125B2 (en) Crystalline forms of a factor XIa inhibitor
JP2019135258A (ja) 第Ｘａ因子阻害剤の結晶形態
TW202031674A (zh) 一類新型二肽類化合物及用途
TWI257389B (en) Pharmaceutical compound
CN1984903A (zh) 1－(吲哚－6－羰基－d－苯基甘氨酰基)－4－(1－甲基哌啶－4－基)哌嗪d－酒石酸盐
JP5959617B2 (ja) オタミキサバンの安息香酸塩
KR100849242B1 (ko) 1(인돌-6-카르보닐-ｄ-페닐글리시닐)-4-(1-메틸피페리딘-4-일) 피페라진 ｄ-타르트레이트
CZ20011216A3 (cs) Benzamidové deriváty
EP2782576B1 (en) Sodium salt of (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
KR20210050472A (ko) 에독사반염 및 이를 포함하는 약제학적 조성물
HK40060683A (en) Novel dipeptide compounds and uses thereof
HK40060683B (en) Novel dipeptide compounds and uses thereof
MX2008005143A (en) Pharmaceutical salts and polymorphs of n- (5-chl0r0-2-pyridinyl) -2- [ [4- [ (dimethylamino) iminomethyl]benzoyl]amino]-5-meth oxy-benzamide, a factor xa inhibitor
HK1115131B (en) Pharmaceutical salts and polymorphs of n-(5-chloro-2-pyridinyl)-2-[[4-[(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxy-benzamide , a factor xa inhibitor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication